Involvement Of The Cyclin-Dependent Kinase Inhibitor p16 (INK4a)In Replicative Senescence Of Normal Human Fibroblasts by D. A. Alcorta, Y. Xiong, D. Phelps, G. Hannon, D. Beach, and J. C. Barrett. Proc Natl Adam Sci USA, Nov. 1996, 26:93(24): 13742-7. |
Inhibition Of Proliferation And Induction Of Differentiation In Medulloblastoma- And Astrocytoma-Derived Cell Lines With Phenylacetate by G. Stockhammer, G. T. Manley, R. Johnson, M. K. Rosenblum, D. Samid, and F. S. Liberman. Journal of Neurosurgery. 83(4):672-81, Oct. 1995. |
Phenylbutyrate (PB) For Refractory Solid Tumors: A Phase I Clinical And Pharmacological Evaluation (Meeting Abstract) by M. Carducci, M. Bowling, M. Eisenberger, V. Sinibaldi, J. Simons, T. Chen, D. Noe, L. Grochow, and R. Donehower. Anticancer Research, 17:3921-3982 (1997). |
Therapeutic Targeting of Transcription in Acute Promyelocytic Leukemia by Use of an Inhibitor of Histone Deacetylase by R. P. Warrell, L-Z. He, V. Richon, E. Calleja, and P. R. Pandolfi. Journal of the National Cancer Institute, vol. 90, No. 21, Nov. 4, 1998. |
A Novel Approach for Nasopharyngeal Carcinoma Treatment Uses Phenylbutyrate as a Protein Kinase C Modulator: Implications for Radiosensitization and EBV-targeted Therapy by Y-L. Chung, Y-H. Wu Lee, S-H. Yen, and K-H Chi. Clinical Cancer Research, vol. 6, 1452-1458, Apr. 2000. |
Pharmacological Manipulation Of Gene Expression Brings New Hope to The Treatment Of X-Linked Adrenoleukodystrophy by Ronald J. A. Wanders. Nature Medicine, vol. 4, No. 11, Nov. 1998. |